vs

Side-by-side financial comparison of Arcus Biosciences, Inc. (RCUS) and UNITED BANCORP INC (UBCP). Click either name above to swap in a different company.

Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $6.9M, roughly 1.6× UNITED BANCORP INC). UNITED BANCORP INC runs the higher net margin — 29.6% vs -963.6%, a 993.2% gap on every dollar of revenue. On growth, UNITED BANCORP INC posted the faster year-over-year revenue change (8.6% vs -52.2%). UNITED BANCORP INC produced more free cash flow last quarter ($-1.3M vs $-121.0M). Over the past eight quarters, Arcus Biosciences, Inc.'s revenue compounded faster (4.9% CAGR vs -0.7%).

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

United Bank was an American bank headquartered in Hartford, Connecticut, and had locations throughout Connecticut, Massachusetts and Rhode Island. The bank was acquired in 2019 by People's United Financial and branches were rebranded or closed.

RCUS vs UBCP — Head-to-Head

Bigger by revenue
RCUS
RCUS
1.6× larger
RCUS
$11.0M
$6.9M
UBCP
Growing faster (revenue YoY)
UBCP
UBCP
+60.8% gap
UBCP
8.6%
-52.2%
RCUS
Higher net margin
UBCP
UBCP
993.2% more per $
UBCP
29.6%
-963.6%
RCUS
More free cash flow
UBCP
UBCP
$119.7M more FCF
UBCP
$-1.3M
$-121.0M
RCUS
Faster 2-yr revenue CAGR
RCUS
RCUS
Annualised
RCUS
4.9%
-0.7%
UBCP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RCUS
RCUS
UBCP
UBCP
Revenue
$11.0M
$6.9M
Net Profit
$-106.0M
$2.0M
Gross Margin
Operating Margin
-1036.4%
28.7%
Net Margin
-963.6%
29.6%
Revenue YoY
-52.2%
8.6%
Net Profit YoY
-12.8%
10.1%
EPS (diluted)
$-0.88
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCUS
RCUS
UBCP
UBCP
Q4 25
$11.0M
$6.9M
Q3 25
$6.0M
$8.1M
Q2 25
$8.0M
$8.0M
Q1 25
$8.0M
$7.5M
Q4 24
$23.0M
$6.3M
Q3 24
$7.0M
$7.4M
Q2 24
$11.0M
$7.4M
Q1 24
$10.0M
$7.0M
Net Profit
RCUS
RCUS
UBCP
UBCP
Q4 25
$-106.0M
$2.0M
Q3 25
$-135.0M
$1.9M
Q2 25
$0
$1.9M
Q1 25
$-112.0M
$1.9M
Q4 24
$-94.0M
$1.8M
Q3 24
$-92.0M
$1.8M
Q2 24
$-93.0M
$1.7M
Q1 24
$-4.0M
$2.0M
Operating Margin
RCUS
RCUS
UBCP
UBCP
Q4 25
-1036.4%
28.7%
Q3 25
-2366.7%
23.7%
Q2 25
-100.0%
24.2%
Q1 25
-1525.0%
24.5%
Q4 24
-447.8%
28.1%
Q3 24
-1500.0%
23.9%
Q2 24
-963.6%
21.8%
Q1 24
-160.0%
30.7%
Net Margin
RCUS
RCUS
UBCP
UBCP
Q4 25
-963.6%
29.6%
Q3 25
-2250.0%
23.9%
Q2 25
24.0%
Q1 25
-1400.0%
24.9%
Q4 24
-408.7%
29.1%
Q3 24
-1314.3%
24.7%
Q2 24
-845.5%
23.6%
Q1 24
-40.0%
28.5%
EPS (diluted)
RCUS
RCUS
UBCP
UBCP
Q4 25
$-0.88
$0.35
Q3 25
$-1.27
$0.34
Q2 25
$0.00
$0.33
Q1 25
$-1.14
$0.32
Q4 24
$-1.07
$0.31
Q3 24
$-1.00
$0.31
Q2 24
$-1.02
$0.30
Q1 24
$-0.05
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCUS
RCUS
UBCP
UBCP
Cash + ST InvestmentsLiquidity on hand
$222.0M
$46.5M
Total DebtLower is stronger
$99.0M
Stockholders' EquityBook value
$631.0M
$70.5M
Total Assets
$1.1B
$857.4M
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCUS
RCUS
UBCP
UBCP
Q4 25
$222.0M
$46.5M
Q3 25
$238.0M
$45.7M
Q2 25
$248.0M
$49.7M
Q1 25
$192.0M
$36.4M
Q4 24
$150.0M
$19.6M
Q3 24
$201.0M
$37.8M
Q2 24
$156.0M
$37.6M
Q1 24
$185.0M
$46.9M
Total Debt
RCUS
RCUS
UBCP
UBCP
Q4 25
$99.0M
Q3 25
$98.0M
Q2 25
$97.0M
Q1 25
$48.0M
Q4 24
$48.0M
Q3 24
$47.0M
Q2 24
Q1 24
Stockholders' Equity
RCUS
RCUS
UBCP
UBCP
Q4 25
$631.0M
$70.5M
Q3 25
$436.0M
$66.5M
Q2 25
$549.0M
$59.7M
Q1 25
$531.0M
$60.8M
Q4 24
$485.0M
$63.5M
Q3 24
$565.0M
$65.5M
Q2 24
$635.0M
$60.6M
Q1 24
$707.0M
$63.2M
Total Assets
RCUS
RCUS
UBCP
UBCP
Q4 25
$1.1B
$857.4M
Q3 25
$974.0M
$866.8M
Q2 25
$1.1B
$847.9M
Q1 25
$1.2B
$830.7M
Q4 24
$1.1B
$816.7M
Q3 24
$1.3B
$825.5M
Q2 24
$1.2B
$821.8M
Q1 24
$1.3B
$834.0M
Debt / Equity
RCUS
RCUS
UBCP
UBCP
Q4 25
0.16×
Q3 25
0.22×
Q2 25
0.18×
Q1 25
0.09×
Q4 24
0.10×
Q3 24
0.08×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCUS
RCUS
UBCP
UBCP
Operating Cash FlowLast quarter
$-120.0M
$10.5M
Free Cash FlowOCF − Capex
$-121.0M
$-1.3M
FCF MarginFCF / Revenue
-1100.0%
-19.2%
Capex IntensityCapex / Revenue
9.1%
171.0%
Cash ConversionOCF / Net Profit
5.14×
TTM Free Cash FlowTrailing 4 quarters
$-819.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCUS
RCUS
UBCP
UBCP
Q4 25
$-120.0M
$10.5M
Q3 25
$-97.0M
$3.2M
Q2 25
$-133.0M
$3.8M
Q1 25
$-132.0M
$1.1M
Q4 24
$-100.0M
$8.4M
Q3 24
$26.0M
$4.4M
Q2 24
$-94.0M
$-789.0K
Q1 24
$-2.0M
$3.6M
Free Cash Flow
RCUS
RCUS
UBCP
UBCP
Q4 25
$-121.0M
$-1.3M
Q3 25
$-367.0K
Q2 25
$1.5M
Q1 25
$-133.0M
$-594.0K
Q4 24
$-101.0M
$-1.2M
Q3 24
$25.0M
$-1.7M
Q2 24
$-1.5M
Q1 24
$-6.0M
$223.0K
FCF Margin
RCUS
RCUS
UBCP
UBCP
Q4 25
-1100.0%
-19.2%
Q3 25
-4.5%
Q2 25
18.3%
Q1 25
-1662.5%
-7.9%
Q4 24
-439.1%
-19.7%
Q3 24
357.1%
-22.9%
Q2 24
-20.5%
Q1 24
-60.0%
3.2%
Capex Intensity
RCUS
RCUS
UBCP
UBCP
Q4 25
9.1%
171.0%
Q3 25
0.0%
43.7%
Q2 25
0.0%
29.0%
Q1 25
12.5%
22.0%
Q4 24
4.3%
152.8%
Q3 24
14.3%
82.8%
Q2 24
0.0%
9.8%
Q1 24
40.0%
48.6%
Cash Conversion
RCUS
RCUS
UBCP
UBCP
Q4 25
5.14×
Q3 25
1.64×
Q2 25
1.98×
Q1 25
0.57×
Q4 24
4.57×
Q3 24
2.42×
Q2 24
-0.45×
Q1 24
1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

UBCP
UBCP

Segment breakdown not available.

Related Comparisons